Status
Conditions
Treatments
About
This is a multicenter, non-interventional, retrospective study (with two prospective cohorts), including previously treated patients with melanoma, squamous cell lung cancer in the late stages (inoperable or metastatic) and Hodgkin disease at any stages.
The duration of the follow-up will be 12-60 months. Data from medical records will be retrospectively collected at different points in time. The first data extraction will consist of collecting data from the initial level (before treatment with immune checkpoints inhibitors (anti-PD1 / PDl1) before the end of the recruitment period for this study (up to 3 years of follow-up). Two additional annual data collections are planned for display additional follow-up and data for patients who will survive.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
To participate in this study, the patient must meet the following criteria:
Specific inclusion criteria for individual cohorts:
Cohort 1 (retrospective cohort of skin melanoma patients)
Cohort 2 (Hodjkin disease - retrospective)
Cohort 3 (Uveal melanoma - retro)
Cohort 4 (melanoma of the skin - prospective)
Cohort 5 (squamous cell lung cancer - prospective)
Exclusion criteria
Cohort 1 (retrospective cohort of skin melanoma patients)
Cohort 2 (Hodgkin disease - retrospective)
no special exclusion criteria
Cohort 3 (Uveal melanoma - retro)
Cohort 4 (melanoma of the skin - prospective)
Cohort 5 (squamous cell lung cancer - prospective)
350 participants in 5 patient groups
Loading...
Central trial contact
Irina Mikhaylova, MD, PhD; Igor Samoylenko, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal